Events

Brokerage event - Horizon Europe EU Missions (2025 calls)
MAY
Mon
26
MAY
Tue
27

This was 7 months ago

Location

Online

Programmes
Health Climate, Energy, Mobility Agro-Food, Environment Missions

Do you intend to prepare a proposal addressing a topic under the upcoming EU Missions calls in Horizon Europe?

The network of National Contact Points for the EU Missions, NCP4Missions, organises an online brokerage event dedicated to consortium building in the EU Missions: Cancer Mission; Adaptation to climate change Mission; Soil deal Mission; Climate-neutral & smart cities Mission; Ocean and Waters Mission

Schedule for the EU Missions brokerage event:

  • 26 May 10 - 11 am: Plenary session
  • 26 May 11 am - 7 pm: Bilateral meetings
  • 27 May 10 am - 7 pm: Bilateral meetings


The event is free of charge but registration and profile activation are mandatory to attend. 

More information and registration (open until 22 May) on the event website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.